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Introduction: The epidermal growth factor receptor inhibitor erlo-
tinib is an approved treatment for chemotherapy-refractory advanced 
non–small-cell lung cancer (NSCLC). Because activated epidermal 
growth factor receptor signals through the phosphatidylinositol 
3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway, add-
ing the oral mTOR inhibitor everolimus to erlotinib may improve 
efficacy by blocking multiple components of the same pathway. We 
conducted a phase I study to determine feasible dosages of combi-
nation therapy with erlotinib and everolimus for previously treated 
metastatic or unresectable NSCLC.
Methods: Participants had advanced NSCLC progressing after 
two or less previous chemotherapy regimens. Feasibility of daily/
weekly everolimus plus daily erlotinib was determined using a 6 + 6 
dose-escalation design based on the rate of dose-limiting toxicities. 
Antitumor activity was assessed by the Response Evaluation Criteria 
In Solid Tumors study.
Results: Of the 94 patients enrolled, 90% had stage IV NSCLC, 19% 
never smoked, and 15% were current smokers. Eighty-nine patients 
experienced one or more adverse events possibly related to any study 
medication. The most common dose-limiting toxicities were stoma-
titis (n = 5), rash (n = 4), and diarrhea (n = 3). Maximum tolerated 
doses were everolimus 5 mg per day or 50 mg per week plus erlotinib 
150 mg per day. In daily everolimus cohorts (n = 74), nine patients 
achieved a complete/partial response and 28 had stable disease 
(median duration disease control, 9.3 months). In weekly everolimus 
cohorts (n = 20), no tumor response was observed; seven patients had 
stable disease (median duration, 9.6 months).
Conclusions: Combination therapy with everolimus 5 mg per day or 
50 mg per week and erlotinib 150 mg per day provided acceptable 
tolerability and disease control. A randomized phase II study evaluat-
ing this combination in comparison with erlotinib alone is complete 
and is being analyzed.
Key Words: Dose-limiting toxicity, Erlotinib, Everolimus, Non–
small-cell lung cancer, Phase I.
(J Thorac Oncol. 2012;7: 1594–1601)
Worldwide, lung cancer causes almost 1.4 million deaths each year, making it the most common cause of cancer 
death.1 Approximately 85% of lung cancers are non–small-cell 
lung cancer (NSCLC).2 The prognosis for patients with advanced 
NSCLC is generally poor; in the United States, the 5-year survival 
rate for patients with distant metastases was only 3.8% between 
2001 and 2007.3 Depending on the stage of the disease, current 
treatment options for NSCLC include surgery; radiotherapy; 
chemotherapy; and targeted therapies, including the antiangio-
genic agent bevacizumab, the epidermal growth factor receptor 
(EGFR) inhibitors erlotinib, gefitinib, and cetuximab, and the 
anaplastic lymphoma kinase inhibitor crizotinib.2,4–7 Erlotinib is 
an inhibitor of EGFR-associated tyrosine kinase activity. EGFR 
mediates cell proliferation, cell migration, and cell survival in 
lung cancer cells.8 Administered orally once daily, erlotinib is 
currently the only EGFR inhibitor approved in the United States 
for the treatment of patients with previously treated, advanced 
NSCLC.2 The use of erlotinib in treatment-refractory NSCLC is 
supported by the results of a phase III study that demonstrated 
significant prolongation of survival (compared with placebo) in 
patients with stage IIIb or IV NSCLC, whose disease progressed 
after platinum-based therapy.9
Whereas patients with wild-type EGFR derive lim-
ited benefit from treatment with EGFR inhibitors,10 patients 
who carry activating mutations of EGFR show a high 
sensitivity to EGFR-targeted therapy, which correlates with 
dramatic clinical responses.11,12 Because activated EGFR 
signals through the PI3K/Akt/mammalian target of rapamycin 
(mTOR) pathway,13 one potential way to further improve the 
therapeutic efficacy of EGFR-targeted therapy in patients 
with wild-type EGFR receptors, where erlotinib has modest 
antitumor activity, is to combine an EGFR inhibitor with an 
mTOR inhibitor, thus blocking multiple components of the 
same signaling pathway.
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Everolimus is an oral inhibitor of mTOR, a serine-
threonine kinase that stimulates cell growth, proliferation, 
and angiogenesis in mammalian cells.13 Everolimus is cur-
rently approved in the United States as anticancer therapy for 
the treatment of sunitinib- or sorafenib-refractory advanced 
renal cell carcinoma (RCC); progressive, unresectable, locally 
advanced or metastatic pancreatic neuroendocrine tumors 
(pNET); and subependymal giant cell astrocytoma associ-
ated with tuberous sclerosis that is not amenable to surgery.14 
Dysregulation of signal transduction via the PI3K/Akt/mTOR 
pathway has been implicated in the pathogenesis of NSCLC 
and the acquisition of resistance to chemo- and radiother-
apy, as well as EGFR-targeted therapy.15–17 Consistent with 
a possible role of the PI3K/A kt/mTOR pathway in NSCLC, 
everolimus administered at 10 mg per day showed modest 
antitumor activity (4.7% response rate and 47% disease- 
control rate at 8 weeks) in 85 patients with NSCLC previously 
treated with chemotherapy alone or chemotherapy plus an 
EGFR inhibitor.18 Results of preclinical studies further sug-
gest that the combination of an mTOR inhibitor and erlotinib 
may have synergistic antitumor activity in NSCLC.19,20 Thus, 
there is adequate evidence to test the hypothesis that everoli-
mus plus erlotinib might provide greater therapeutic benefits 
than erlotinib monotherapy in previously treated patients with 
advanced NSCLC.
The primary objective of this study was to assess the 
feasibility of different doses and dose schedules of everoli-
mus and erlotinib for second- and third-line combination 
therapy in patients with metastatic NSCLC. Both daily and 
weekly dosing schedules of everolimus were investigated 
because previous pharmacodynamic studies in advanced solid 
tumors indicated that inhibition of mTOR signaling and anti-
tumor activity were observed with both dosing schedules.21–23 
Starting doses for both drugs were based on experience from 
previous clinical studies that evaluated the safety and efficacy 
of everolimus or erlotinib in this patient population.9,18 Both 
daily and weekly everolimus dosing were explored to iden-
tify the optimal schedule in terms of pharmacokinetics and 
tolerability.
PATIENTS AND METHODS
Patients
Study participants were aged 18 years or olderand had 
advanced, pathologically confirmed NSCLC that showed pro-
gression on serial computed tomography scans despite one or 
two previous chemotherapy regimens, at least one of which 
included cisplatin or carboplatin. Additional inclusion criteria 
were a World Health Organization performance status of 2 or 
less and adequate bone marrow and hepatic function. Both 
smokers and nonsmokers (defined as patients who smoked 
fewer than 100 cigarettes in a lifetime) were included in the 
study. Patients previously treated with an EGFR inhibitor or 
requiring concurrent treatment with an agent also used in the 
treatment of cancer, receiving chronic therapy with steroids 
or immunosuppressive agents, or who had received another 
investigational agent in the previous 4 weeks were excluded. 
Other exclusion criteria were leptomeningeal or uncontrolled 
brain metastases, malignancies other than lung cancer in the 
previous 2 years (except for adequately treated cervical car-
cinoma, basal cell carcinoma, or squamous cell carcinoma), 
evidence of human immunodeficiency virus infection, impair-
ment of gastrointestinal function that may significantly alter 
absorption of a study drug, and any concurrent severe or 
uncontrolled disease that could compromise study participa-
tion. All patients provided written informed consent. The study 
protocol was approved by the Institutional Review Boards of 
all institutions, and the study was conducted in accordance 
with the principles of the Declaration of Helsinki and amend-
ments concerning medical research in humans.
Study Design and Treatments
This phase I study was a multicenter, open-label, nonrandom-
ized, sequential dose-escalation study. The study assessed the 
dose-limiting toxicities (DLTs) of daily and weekly doses of 
oral everolimus in combination with daily oral erlotinib in 
previously treated patients with advanced NSCLC to deter-
mine the feasible dose and schedule of combination therapy. 
Patients were enrolled in groups of six per dose cohort, with 
enrollment alternating between daily and weekly cohorts. 
Once the maximum tolerated dose (MTD) for a given sched-
ule was determined, enrollment in that schedule was stopped. 
Dose-escalation decisions were as follows: If two of six 
patients in any dose cohort experienced a DLT, six additional 
patients were enrolled in the same cohort. The dose of everoli-
mus or erlotinib was escalated if one or no DLT was observed 
in six patients or if three or fewer DLTs were observed in 12 
patients. If four or more DLTs were observed in 12 patients of 
any cohort, an additional six patients were enrolled at the pre-
vious dose level (up to 12 in total); if 12 patients were already 
enrolled at the lower dose level, this level was declared the 
MTD. At all decision-making time points, the clinical opinion 
of the investigators was considered together with the dose-
escalation criteria.
Starting doses for the daily and weekly everolimus 
schedules were everolimus 2.5 mg per day plus erlotinib 100 
mg per day and everolimus 30 mg per week plus erlotinib 150 
mg per day. The planned everolimus doses were 5 mg every 
other day (replaced by 2.5 mg/day after an interim pharma-
cokinetic assessment), 5 mg per day, 10 mg per day, 20 mg 
per week, 30 mg per week, and 50 mg per week. The planned 
erlotinib doses were 50 mg per day, 75 mg per day, 100 mg 
per day, and 150 mg per day. In all cohorts, patients received 
a single dose of erlotinib on day 1, followed by a 24-hour 
concentration profile. Treatment was withheld until day 8, at 
which point erlotinib and everolimus were initiated accord-
ing to the dose and schedule specified by the dose-escalation 
scheme. Partially overlapping toxicities were anticipated to be 
more severe with the full dose of erlotinib recommended as a 
single agent for relapsed NSCLC (150 mg/day) and the 10 mg 
per day dose of everolimus approved for advanced RCC and 
progressive, advanced pNET.
The following adverse events were considered to be 
DLTs if they occurred in the first cumulative 28 days of com-
bined treatment and were suspected to be related to a study 
drug: grade 3 or 4 nonhematologic toxicity (except hypercho-
lesterolemia, hypertriglyceridemia, or hyperglycemia) despite 
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appropriate therapy or grade 3 or 4 neutropenia or thrombocy-
topenia. After the three cohorts completed the daily dosing 
regimen, mucositis that rapidly resolved after treatment inter-
ruption was observed as the predominant DLT; therefore, the 
nonhematologic DLT criteria were modified and redefined as 
grade 3 nonhematologic toxicity (except hypercholesterol-
emia, hypertriglyceridemia, or hyperglycemia) that did not 
resolve to grade 2 or lower within 7 days of treatment inter-
ruption or that, despite appropriate therapy, recurred after 
treatment interruption within the first cumulative 28 days of 
combined treatment; other DLT criteria remained the same.
Assessments and Analyses
Safety evaluations included continuous monitoring of adverse 
events and regular assessment of vital signs, physical condi-
tion, and clinical laboratory tests. Adverse events were clas-
sified according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events, version 3.0.24 The 
safety population included all patients who received one or 
more dose of the study drug and had a postbaseline safety 
assessment. The MTD-determining population included all 
patients who received 28 or more cumulative days of combi-
nation treatment with everolimus and erlotinib and completed 
all required safety evaluations or who experienced a DLT 
within 28 days of combination treatment with everolimus 
and erlotinib.
Tumor assessments were performed by computed 
tomography scans every 4 weeks for the first 16 weeks after 
the first combined administration of everolimus and erlotinib 
and every 8 weeks thereafter. Tumor response was assessed 
within 7 days of the scheduled date according to the Response 
Evaluation Criteria In Solid Tumors.25 Efficacy was assessed 
in the full analysis set, defined as all patients who received one 
or more doses of any study drug, and the per-protocol popula-
tion, defined as all patients who received one or more doses of 
any study drug and had a baseline assessment and one or more 
postbaseline tumor assessments after 5 weeks.
Blood samples for pharmacokinetic analysis of the daily 
everolimus schedule were collected predose and 1, 2, 5, 8, and 
24 hours postdose on days 8 and 22; samples for analysis of 
the weekly everolimus schedule were collected predose on 
day 8 and 1, 2, 4, 24, and 168 hours postdose. Regardless of 
the everolimus schedule, blood samples for the evaluation of 
erlotinib were collected predose and 1, 3, 5, 8, and 24 hours 
postdose on days 1, 8, and 22. Trough levels for daily and 
weekly everolimus and daily erlotinib were evaluated once 
a month from week 8 until month 4. An additional blood 
trough level evaluation for the weekly everolimus cohort was 
performed predose on day 22. Blood samples were collected 
by direct venipuncture or an indwelling cannula in a forearm 
vein into a tube containing ethylenediaminetetraacetic acid 
(for everolimus) or heparin (for erlotinib). Everolimus sam-
ples were frozen at or below −20°C until shipment to Novartis 
Bioanalytics (Rueil-Malmaison, France) and WuXi Apptec 
(Shanghai, China) for analysis. Erlotinib samples were fro-
zen at or below –20°C until shipment to MDS Laboratorie 
(Zurich, Switzerland) for analysis. Concentrations of everoli-
mus and erlotinib and its primary metabolite, OSI-420, were 
determined using validated methods. In brief, everolimus con-
centrations were determined from 2-ml whole blood samples 
by a liquid chromatography/mass spectrometry method with a 
lower limit of quantification of 0.3 ng/ml. Erlotinib and OSI-
420 concentrations were determined from 3-ml plasma sam-
ples after liquid/liquid extraction using a high-performance 
liquid chromatograph equipped with an AB/MDS Sciex 4000 
mass spectrometer; the lower limit of quantification for erlo-
tinib and OSI-420 was 1.00 ng/ml each. The pharmacokinetic 
parameters of the maximum concentration (C
max
), time to reach 
C
max
 (t
max
), the trough concentration (C
min
), and the area under 
the curve (AUC) over the dosing interval (AUC
0–tlast
) or to time 
infinity (AUC
0–inf
) were derived by noncompartmental analysis 
using WinNonlin version 5.2 (Pharsight, Mountain View, CA). 
The effect of coadministration of everolimus and erlotinib 
(day 8) on the pharmacokinetics of erlotinib was assessed in 
the MTD-determining population by calculating the geometric 
mean and 90% confidence interval for the ratio of C
max
 and 
AUC of erlotinib plus everolimus to erlotinib alone.
RESULTS
Patients
A total of 94 patients were enrolled in the study from June 14, 
2005 to May 1, 2008. On the basis of dose-escalation crite-
ria for determining the MTD, 74 patients were enrolled in the 
daily dose cohorts and 20 patients in the weekly dose cohorts 
(Table 1). All patients were evaluated for safety, including two 
patients who did not receive everolimus treatment (1 in the 
everolimus 5 mg/day plus erlotinib 100 mg/day cohort; 1 in 
the everolimus 50 mg/week plus erlotinib 150 mg/day cohort). 
The majority of study participants were white, 56% were men, 
and the median age was 60 years. Fewer than 20% of the par-
ticipants had never smoked, and 15% were smokers within 12 
months before the start of or when entering the study. Most 
patients (68%) had adenocarcinomas. Ninety percent of the 
patients had stage IV NSCLC, and two thirds had a World 
Health Organization performance status of 1 (Table 1). By 
December 17, 2009, all but three patients had discontinued 
study participation; there was only one reported death at this 
time. Most participants discontinued because of disease pro-
gression (65%) or adverse events (26%); others discontinued 
because of withdrawal of consent (4%), abnormal laboratory 
test results (1%), or death (1%).
Treatment Exposure and Dose Reductions
Patient exposure to everolimus/erlotinib combination therapy 
is shown in Table 2. Patients who were assigned to receive 
everolimus 5 mg per day plus erlotinib 100 mg per day had 
the longest exposure, with a median of 3.5 months (range, 
0.2–25.8) and a mean of 6.7 months (standard deviation, 
7.66). Overall, the median duration of exposure for the 
weekly cohorts was shorter than that of the daily cohorts 
(Table 2). Among the daily dose cohorts, patients treated 
with everolimus 5 mg plus erlotinib 150 mg experienced the 
least dose reductions or treatment interruptions (25%; 2 of 
8 patients) for each drug. Among weekly dose cohorts, no 
patients receiving everolimus 30 mg plus erlotinib 150 mg 
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had dose reductions or interruptions of everolimus. Dose 
reductions or interruptions in all other daily and weekly dose 
cohorts ranged from 29% to 50% for each drug and were most 
commonly caused by adverse events.
Dose-Limiting Toxicities and Safety
A total of 15 patients (20%) in the six daily everolimus cohorts 
and three patients (15%) in the 2 weekly everolimus cohorts 
experienced DLTs (Table 3). The most common individual 
DLTs were stomatitis (n = 5), rash (n = 4), and diarrhea 
(n = 3). Only one patient experienced a hematologic DLT 
(neutropenia). On the basis of the prespecified DLT criteria 
and the clinical opinion of the investigators, the feasible 
MTDs identified were everolimus 5 mg per day plus erlotinib 
150 mg per day and everolimus 50 mg per week plus erlotinib 
150 mg per day, respectively.
Of the 94 study participants, 89 (95%) experienced one 
or more adverse events suspected to be related to everolimus 
and/or erlotinib. Forty patients (43%) experienced possibe 
drug-related grade 3 or 4 events during treatment; the most 
common were stomatitis (n = 12), rash (n = 5), and diarrhea 
(n = 11). All other possible drug-related grade 3 or 4 events that 
occurred in more than one patient are listed in Table 4. Serious 
adverse events occurred in 51 patients (54%), most commonly 
gastrointestinal disorders (n = 13), infections and infestations 
(n = 11), and respiratory disorders (n = 10). One patient died 
of acute myocardial infarction after 890 days of therapy with 
everolimus 2.5 mg per day plus erlotinib 100 mg per day; the 
death was not suspected to be related to the study drug.
Disease Control
In the full analysis set (N = 94), disease control was achieved 
by 44 patients (47%), with one patient (1%) achieving a com-
plete response (CR), eight patients (9%) achieving a partial 
response (PR), and 35 patients (37%) achieving stable dis-
ease as best overall response (Table 5). The one CR and the 
eight PRs occurred in the daily cohort. The median duration 
of disease control was 9.3 months in the daily dose cohorts 
(n = 74) and 9.6 months in the weekly dose cohorts (n = 
20). Of the 74 patients enrolled in the daily dose cohorts, 
48 patients composed the per-protocol population; disease 
control was achieved by 35 (73%) of these patients, with 
one (1%) achieving a CR and eight (11%) achieving a PR 
as best overall response, and 26 (54%) with stable disease 
(Table 5). Of the nine responders, five were men, four had a 
history of smoking (including 1 current smoker), seven had 
adenocarcinomas, one had squamous cell carcinoma, and 
one had NSCLC of other histology. Of 20 patients enrolled 
in the weekly dose cohorts, 14 composed the per-protocol 
population; disease control was achieved by seven (50%) of 
these patients, all of whom achieved stable disease as best 
overall response (Table 5). In the per-protocol population, 
progressive disease as the best overall response occurred in 
12 patients (25%) in the daily dose cohorts and five patients 
(36%) in the weekly cohorts.
Pharmacokinetics
The pharmacokinetic parameters of everolimus, erlotinib, and 
its principle metabolite OSI-420 were evaluated at all doses 
investigated in this study (data not shown). On the basis of the 
ratio of geometric means and accompanying 90% confidence 
intervals for the C
max
, AUC
0–tlast
, and AUC
0–inf
 of erlotinib 
and OSI-420, everolimus did not significantly influence the 
TABLE 1. Patient Demographic and Baseline Characteristics 
(Full Analysis Set)
Variable
Daily Cohorts 
n = 74
Weekly Cohorts 
n = 20
Total 
N = 94
Age, yrs
 Male, mean ± SD 61 ± 9.5 59 ± 9.0 61 ± 9.4s
 Male, median (range) 61 (35 − 77) 58 (46 − 77) 60 (35 − 77)
Sex, n (%)
 Male 40 (54.1) 13 (65.0) 53 (56.4)
 Female 34 (45.9) 7 (35.0) 41 (43.6)
Race, n (%)
 White 69 (93.2) 19 (95.0) 88 (93.6)
 Black 1 (1.4) 0 1 (1.1)
 Asian 3 (4.1) 0 3 (3.2)
 Other 1 (1.4) 1 (5.0) 2 (2.1)
Smoking history
 Never smoked,a n (%) 14 (18.9) 4 (20.0) 18 (19.1)
  Male; female (n) 6; 8 2; 2 8; 10
 Ever smoked,b n (%) 60 (81.1) 16 (80.0) 76 (80.9)
  Male; female (n) 34; 26 11; 5 45; 31
 Current smoker,c n (%) 10 (13.5) 4 (20.0) 14 (14.9)
  Male; female (n) 5; 5 3; 1 8; 6
Tumor histology, n (%)
 Adenocarcinoma 50 (67.6) 14 (70.0) 64 (68.1)
 Squamous cell  
 carcinoma
8 (10.8) 2 (10.0) 10 (10.6)
 Large cell carcinoma 5 (6.8) 3 (15.0) 8 (8.5)
 Bronchioalveolar  
 carcinoma
1 (1.4) 0 1 (1.1)
 Other 10 (13.5) 1 (5.0) 11 (11.7)
WHO performance  
status, n (%)
 0 19 (25.7) 6 (30.0) 25 (26.6)
 1 49 (66.2) 14 (70.0) 63 (67.0)
 2 6 (8.1) 0 6 (6.4)
Cancer stage, n (%)
 III, IIIb 8 (10.8) 1 (5.0) 9 (9.6)
 IV, Iva 66 (89.2) 19 (95.0) 85 (90.4)
Previous antineoplastic 
therapy, n (%)
74 (100) 20 (100) 94 (100)
 Chemotherapy 74 (100) 20 (100) 94 (100)
 One regimen 45 (60.8) 11 (55.0) 56 (59.6)
 Two regimens 29 (39.2) 9 (45.0) 38 (40.4)
 Immunotherapy 0 1 (5.0) 1 (1.1)
 Targeted therapy 23 (31.1) 7 (35.0) 30 (31.9)
 Other 3 (4.1) 0 3 (3.2)
aDefined as smoking < 100 cigarettes in lifetime.
bDefined as smoking > 100 cigarettes in lifetime.
cDefined as smoking cigarettes within 12 months before the start of or when entering 
the study.
WHO, World Health Organization.
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TABLE 2.  Exposure to Everolimus/Erlotinib Combination Therapy (Safety Population)
Duration, 
months
Daily Cohorts Weekly Cohorts
5/100 
n = 15
5 EOD/100 
n = 12
2.5/100 
n = 13
2.5/150 
n = 13
5/75 
n = 13
5/150 
n = 8
30/150 
n = 6
50/150 
n = 14
Mean ± SD 6.7 ± 7.66 4.7 ± 4.37 6.1 ± 9.62 4.9 ± 7.43 2.6 ± 3.52 4.4 ± 6.62 1.6 ± 0.54 4.1 ± 8.11
Median 3.5 3.1 1.9 2.5 0.7 1.5 1.7 0.9
Range 0.2–25.8 0.3–12.9 0.5–29.0 0.2–27.6 0.3–11.1 0.2–19.8 0.9–2.3 0.2–29.7
All doses are listed as mg of everolimus/mg of erlotinib.
EOD, every other day.
TABLE 3.  Dose-Limiting Toxicities (Safety Population)
System Organ Class/ 
Preferred Term
Daily Cohorts, n
Total Daily, 
n (%)  
n = 74
Weekly Cohorts, n Total 
Weekly,  
n (%) 
n = 20
Total, N 
N = 94
5/100 
n = 15
5 EOD/100 
n = 12
2.5/100 
n = 13
2.5/150 
n = 13
5/75 
n = 13
5/150 
n = 8
30/150 
n = 6
50/150 
n = 14
Total patients with  
dose-limiting toxicities
2 3 4 2 3 1 15 (20.3) 1 2 3 (15.0) 18 (19.1)
Blood and lymphatic system disorders
 Neutropenia 0 0 1 0 0 0 1 (1.4) 0 0 0 1 (1.1)
Gastrointestinal disorders, metabolism, and nutrition disorders
 Diarrhea 0 2 0 0 1 0 3 (4.1) 0 0 0 3 (3.2)
 Dysphagia 1 0 0 0 0 0 1 (1.4) 0 0 0 1 (1.1)
 Nausea 0 0 0 0 1 0 1 (1.4) 0 0 0 1 (1.1)
 Stomatitis 1 1 2 0 1 0 5 (6.8) 0 0 0 5 (5.3)
 Vomiting 0 0 0 0 1 0 1 (1.4) 0 0 0 1 (1.1)
Infections and infestations
 Dermatitis infected 0 0 0 0 0 1 1 (1.4) 0 0 0 1 (1.1)
 Skin infection 0 0 0 0 0 1 1 (1.4) 0 0 0 1 (1.1)
Skin and subcutaneous disorders
 Dermatitis acneiform 0 0 0 0 0 0 0 0 2 2 (10.0) 2 (2.1)
 Dry skin 0 0 0 0 1 0 1 (1.4) 0 0 0 1 (1.1)
 Palmar-plantar  
 erythrodysesthesia
0 0 0 1 0 0 1 (1.4) 0 0 0 1 (1.1)
Rash 0 1 1 1 0 0 3 (4.1) 1 0 1 (5.0) 4 (4.3)
All doses are listed as mg of everolimus/mg of erlotinib.
EOD, every other day.
pharmacokinetics of erlotinib or OSI-420 (Table 6). Similarly, 
erlotinib did not influence the pharmacokinetics of everolimus 
(data not shown).
DISCUSSION
This is the first report of a clinical study evaluating the 
safety and antitumor activity of an mTOR inhibitor in 
combination with erlotinib in previously treated patients 
with advanced NSCLC. The results of this study suggest that 
based on tolerability, the administration of everolimus 5 mg 
day combined with erlotinib 150 mg per day or everolimus 
50 mg per week combined with erlotinib 150 mg per day 
constitutes a feasible combination therapy for this patient 
group. Moreover, clinical responses and disease-control rates 
suggestive of antitumor activity of everolimus plus erlotinib 
were observed in all daily cohorts in this study. Everolimus 
5 mg per day combined with erlotinib 150 mg per day, which 
corresponds to one-half of the everolimus dose recommended 
for patients with RCC and pNET and the full recommended 
dose for erlotinib, was evaluated in the phase II portion 
of this study (data analysis underway). The choice of the 
daily dosing regimen was based on the results of previous 
pharmacodynamics studies that showed that daily everolimus 
administration may ensure more profound inhibition of the 
mTOR pathway than weekly administration.22,23
Observations from clinical studies indicate that evero-
limus and erlotinib have overlapping and potentially additive 
adverse-events profiles, with both drugs exhibiting tenden-
cies to cause stomatitis, rash, and diarrhea.9,18,21,26,27 Consistent 
with these observations, the present study found stomatitis, 
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rash, and diarrhea to be the predominant grade 3 or 4 adverse 
events suspected to be related to treatment, and the predomi-
nant DLTs. Results of a phase III study of erlotinib in patients 
with previously treated, advanced NSCLC showed that daily 
administration of 150 mg erlotinib provided significant 
survival benefits compared with best standard care (6.7 months 
versus. 4.7 months), but also led to treatment discontinuation 
by 5% of the patients who received erlotinib.9 This rate of dis-
continuation is comparable to that reported in other studies of 
erlotinib monotherapy in patients with advanced NSCLC.28 In 
TABLE 5. Best Overall Response
Daily Cohorts, n
Total Daily, 
n (%)
Weekly  
Cohorts, n
Total Weekly, 
n (%) Total, n (%)5/100 5 EOD/100 2.5/100 2.5/150 5/75 5/150 30/150 50/150
Full analysis set, n 15 12 13 13 13 8 74 6 14 20 94
CR 0 0 1 0 0 0 1 (1.4) 0 0 0 1 (1.1)
PR 1 2 1 3 1 0 8 (10.8) 0 0 0 8 (8.5)
SD 9 4 6 4 2 3 28 (37.8) 3 4 7 (35.0) 35 (37.2)
PD 3 3 5 4 8 4 27 (36.5) 3 5 8 (40.0) 35 (37.2)
Unknown 2 3 0 2 2 1 10 (13.5) 0 5 5 (25.0) 15 (16.0)
Disease control 
(CR, PR, or SD)
10 6 8 7 3 3 37 (50.0) 3 4 7 (35.0) 44 (46.8)
Per-protocol 
population, n
10 9 9 8 7 5 48 5 9 14 62
CR 0 0 1 0 0 0 1 (2.1) 0 0 0 1 (1.6)
PR 1 2 1 3 1 0 8 (16.7) 0 0 0 8 (12.9)
SD 9 4 5 3 2 3 26 (54.2) 3 4 7 (50.0) 33 (53.2)
PD 0 2 2 2 4 2 12 (25.0) 2 3 5 (35.7) 17 (27.4)
Unknown 0 1 0 0 0 0 1 (2.1) 0 2 2 (14.3) 3 (4.8)
Disease control 
(CR, PR, or SD)
10 6 7 6 3 3 35 (72.9) 3 4 7 (50.0) 42 (67.7)
All doses are listed as mg of everolimus/mg of erlotinib.
EOD, every other day; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
TABLE 4. Grade 3 or 4 Adverse Events with Suspected Relationship to Study Drugs in More Than One Patient (Safety 
Population)
System Organ Class/Preferred 
Term, n
Daily Cohorts, n
Total Daily, 
n (%) 
n = 74
Weekly 
Cohorts, n
Total Weekly, 
n (%) 
n = 20
Total, n (%) 
N = 94
5/100 
n = 15
5 EOD/100 
n = 12
2.5/100 
n = 13
2.5/150 
n = 13
5/75 
n = 13
5/150 
n = 8
30/150 
n = 6
50/150 
n = 14
Blood and lymphatic system disorders
 Anemia 0 0 0 0 2 0 2 (2.7) 0 0 0 2 (2.1)
 Neutropenia 0 0 1 0 0 0 1 (1.4) 0 1 1 (5.0) 2 (2.1)
Gastrointestinal disorders, metabolism and nutrition disorders
 Diarrhea 2 3 0 3 2 1 11 (14.9) 0 0 0 11 (11.7)
 Stomatitis 3 1 2 1 2 1 10 (13.5) 1 1 2 (10.0) 12 (12.8)
Skin and subcutaneous tissue disorders
 Dermatitis acneiform 0 0 0 0 0 0 0 0 2 2 (10.0) 2 (2.1)
Palmar-plantar erythrodysesthesia 
syndrome
0 0 0 1 0 1 2 (2.7) 0 0 0 2 (2.1)
 Rash 1 1 1 1 0 0 4 (5.4) 1 0 1 (5.0) 5 (5.3)
Other disorders
 Alanine aminotransferase increased 0 0 0 1 1 0 2 (2.7) 0 0 0 2 (2.1)
 Dehydration 0 0 0 0 2 0 2 (2.7) 1 0 1 (5.0) 3 (3.2)
 Hypokalemia 0 0 0 0 1 0 1 (1.4) 0 1 1 (5.0) 2 (2.1)
All doses are listed as mg of everolimus/mg of erlotinib. A patient with multiple occurrences of a single adverse event is counted only once in that adverse event category.
EOD, every other day.
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the present study, 26% of the patients discontinued treatment 
because of adverse events. Therefore, dose reduction or tem-
porary interruption of therapy may be needed for patients who 
cannot tolerate the daily combination regimen of everolimus 
5 mg plus erlotinib 150 mg. Antitumor activity was observed 
more consistently with daily dosing of everolimus; everolimus 
doses were interrupted and adjusted during the trial to admin-
ister erlotinib at the dose approved by the U.S. Food and Drug 
Administration. This large sample provided the investigators 
with substantial confidence and experience with the chosen 
phase II dosing schedule.
Preliminary disease-control rates observed in the current 
study with erlotinib and everolimus combination therapy 
seems to compare favorably to that reported in previous 
clinical studies of erlotinib or everolimus monotherapy as 
second- or third-line therapy for advanced NSCLC.9,18 In 
the current study, patients in the daily everolimus cohorts 
achieved a disease-control rate of 50% (37 of 74) in the full 
analysis set (73% in the per-protocol population), with nine 
of 74 patients (12%) (19% in the per-protocol population) 
experiencing a CR or PR as the best overall response; median 
duration of stable disease was 9.3 months. In the weekly 
everolimus cohorts, seven of 20 patients (35%) in the full 
analysis set (50% in the per-protocol population) had stable 
disease as the best overall response, with a median duration 
of 9.6 months. In comparison, a phase III study of erlotinib 
conducted in 427 patients with previously treated advanced 
NSCLC resulted in 8.9% of erlotinib recipients achieving 
a CR or PR and 45% achieving disease control; the median 
duration of response was 7.9 months with erlotinib alone.9 
In a phase II study of everolimus 10 mg daily in 85 patients 
with previously treated, advanced NSCLC, 4.7% of patients 
achieved a PR, and disease control was achieved in 47% of 
patients.18 Data on the feasibility of combination therapy 
with everolimus and the EGFR inhibitor gefitinib are also 
available. In a phase I study of 10 patients with previously 
treated, advanced NSCLC, two patients achieved a PR that 
was maintained for 4 months in one patient and 5 months in the 
other. Of note, neither of these patients demonstrated EGFR 
mutations previously associated with gefitinib response.29 
In the cohort of 31 patients with previously treated disease 
enrolled in a phase II study of everolimus 5 mg per day plus 
gefitinib 250 mg per day, three (9.7%) experienced a PR and 
17 (54.8%) achieved stable disease that lasted for a median 
of 3 months; in this phase II study, one of the three patients 
who experienced a PR had an EGFR-activating mutation.30 
Although interpretation of the efficacy results of the present 
study is limited by the lack of EGFR mutation status from 
tumors of responding patients, the results in this molecularly 
unselected population suggest that combination treatment 
with erlotinib and everolimus may be superior to treatment 
with erlotinib alone.
TABLE 6.  Ratio of Geometric Means and 90% Confidence Intervals for Pharmacokinetic Parameters of Erlotinib and OSI-420 
(Safety Population)
Parameter
Daily Cohorts Weekly Cohorts
Postamendment Postamendment Preamendment
5/100 5 EOD/100 5/100 2.5/100 2.5/150 5/75 5/150 30/150 50/150
Erlotinib
 C
max
, ng/ml  na 5/5 11/10 7/8 12/11 12/12 7/6 5/6 10/11
GMR (90% CI) 1.046  
(0.676–1.617)
1.232  
(0.976–1.554)
0.974  
(0.579–1.638)
0.923  
(0.739–1.153)
1.123  
(0.888–1.419)
1.297  
(0.885–1.900)
0.989  
(0.738–1.325)
1.172  
(0.922–1.490)
 AUC
0–tlast
,  
ng·h/ml
na 5/0 9/0 5/4 10/9 9/9 5/5 5/5 7/8
GMR (90% CI) NA NA 0.858  
(0.473–1.556)
0.951  
(0.830–1.089)
1.184  
(0.942–1.488)
1.347  
(0.775–2.343)
0.820  
(0.620–1.083)
1.278  
(0.989–1.651)
 AUC
0–inf
, 
ng·h/ml
n 5/2 9/8 5/4 10/10 9/9 5/5 5/5 7/8
GMR (90% CI) 3.139  
(0.576–17.120)
1.652  
(0.573–4.760)
0.714  
(0.509–1.002)
1.030  
(0.824–1.287)
1.347  
(1.059–1.714)
1.413  
(0.805–2.482)
0.781  
(0.294–2.077)
1.302  
(1.142–1.485)
OSI-420
 C
max
, ng/ml na 5/5 10/8 7/8 10/11 11/10 6/8 5/5 10/11
GMR (90% CI) 0.987  
(0.665–1.465)
1.054  
(0.762–1.458)
1.135  
(0.679–1.897)
1.017  
(0.622–1.662)
1.139  
(0.778–1.668)
1.451  
(1.228–1.714)
1.059  
(0.697–1.611)
1.046  
(0.788–1.390)
 AUC
0–tlast
, 
ng·h/ml
na 2/0 90/ 5/6 9/9 9/9 4/4 5/3 7/8
GMR (90% CI) NA NA 1.011  
(0.682–1.499)
1.153  
(0.665–2.000)
1.307  
(0.932–1.833)
1.699  
(0.819–3.525)
0.867  
(0.545–1.381)
1.264  
(0.919–1.739)
 AUC
0–inf
, 
ng·h/ml
na 3/2 9/8 5/6 10/9 9/8 4/4 5/3 7/8
GMR (90% CI) 1.880 (NA) 2.011 
(1.083–3.734)
1.173  
(0.451–3.050)
1.466  
(0.809–2.655)
1.578  
(0.958–2.599)
1.681  
(0.705–4.009)
0.783  
(0.530–1.155)
1.252  
(1.112–1.410)
All doses are listed as mg of everolimus/mg of erlotinib.
aPresented as number of samples available for erlotinib plus everolimus/number of samples available for erlotinib alone.
GMR presented as geometric mean of erlotinib plus everolimus to geometric mean of erlotinib alone. Geometric means were obtained by back-transforming the mean of the log-
transformed parameter on the original scale.
The log-transformed pharmacokinetic parameter is modeled by means of a linear model adjusted for the profile day as a fixed effect and the patient as a random effect.
EOD, every other day; GMR, geometric mean ratio; NA, not available.
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Few treatment options are available for patients with 
advanced NSCLC whose first- or second-line therapy fails.2,4,7,31 
Currently, erlotinib is the only treatment recommended by pro-
fessional oncology societies in the United States and Europe 
as third-line therapy for patients with stage IV NSCLC.2,4,7 
The present phase I trial demonstrated that the combination of 
everolimus 5 mg per day or 50 mg per week and erlotinib 150 
mg per day had acceptable tolerability in patients with meta-
static NSCLC that progressed on previous therapy. Given the 
improved disease-control rates of this combination compared 
with previous data obtained with erlotinib alone, everolimus 
5 mg per day combined with erlotinib 150 mg per day was 
compared with erlotinib 150 mg per day alone in a randomized 
phase II study of second- or third-line therapy for patients with 
NSCLC. This trial is complete, and data analysis is underway.
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